Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 02 May 2017, Paris - France

Session Details

Poster session 3: Chronic heart failure
Mon 01 May 08:30 - 18:00 Miscellaneous Poster Session Poster Area -

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Time
 
FP Nr
 
Title
 
Speakers
 
Related documents
08:30P1657Asymptomatic left ventricular dysfunction is a predictor of short and long-term mortality among patients with myocardial infarction in southeast Asia: Is there a difference between gender?Jakrin KEWCHAROEN (Bangkok, Thailand)
08:30P1658Clinical features of patients with heart failure with very reduced ejection fraction (hfvref)Eduardo Julian Jose CHUQUIURE (Mexico City, Mexico)
08:30P1659Heart failure with mid range ejection fraction (HFmrEF): a retrospective observational study in a single centre in the eastern province of Saudi ArabiaMaryam AL QASEER (Manama, Bahrain)
08:30P1660A systematic review of clinical prediction rules for the diagnosis of chronic heart failure in the community and their validation in a novel cohortChris WATSON (Belfast, United Kingdom)
08:30P1661Test-retest-Reliability of explorative measurement of CEC and EPC from peripheral blood in patients with systolic and diastolic heart failure, diabetic nephropathy and arterial hypertensionElvis TAHIROVIC (Berlin, Germany)
08:30P1662Time trends in the use and appropriateness of natriuretic peptide testing in primary careFrans Hendrik RUTTEN (Utrecht, Netherlands)
08:30P1663Non-invasive monitoring of peripheral and cardiac influence on exercise limitation in patients with heart failure with preserved ejection fractionDjawid HASHEMI (Berlin, Germany)
08:30P1664Arterial stiffness indices in a chronic heart failure population: a comparison between preserved and reduced ejection fraction populationLuiz Claudio DANZMANN (Porto Alegre, Brazil)
08:30P1665Severe retinal endothelial dysfunction in patients with ischemic cardiomyopathyJens BARTHELMES (Zurich, Switzerland)
08:30P1666Lipids, oxidative stress and inflammation as sex-specific predictors of systolic left ventricular dysfunction in acute coronary syndromeNia SEMERDZIEVA (Sofia, Bulgaria)
08:30P1667Wearable defibrillator protected optimization of therapy and development of LVEF in newly diagnosed heart failureHerbert NAEGELE (Hamburg, Germany)
08:30P1668Remote results of percutaneous coronary interventions at patients chd with reduced of the left ventricle contractility 
08:30P1669Heart failure nurses, luxury or necessity? a substudy of the INTERACT-in-hf (improving knowledge transfer to efficaciously raise level of contemporary treatment in heart failure) studyKarolien BALDEWIJNS (Geel, Belgium)
08:30P1670A French national observational study on 2013 ESC Heart Failure guidelines: Impact on therapeutic management of chronic heart failure patients by office based cardiologists: RECO-Coeur studyPascal DE GROOTE (Lille, France)
08:30P1672LCZ696 compassionate use progamme at mater dei hospital, maltaLisa Lauren BUTTIGIEG (Attard, Malta)
08:30P1673Comparison of ischemic and non-ischemic heart failure outpatients in a Turkish cohortCihan ALTIN (Izmir, Turkey)
08:30P1674Quality of life predicts exercise capacity in heart failure patientsArtan AHMETI (Prishtine, Kosovo Republic of)
08:30P1675Building bridges between primary and secondary/tertiary care: technology driven integrated care in the area of heart failure 
08:30P1676Characteristics, treatments, and outcomes of patients hospitalized for heart failure: a report from the OPTIMIZE-HF Registry (Azerbaijan)Gulnaz DADASHOVA (Baku, Azerbaijan)
08:30P1677Diagnosis of myocardial viability in patients with chronic heart failure: search for the best methodsYasmin RUSTAMOVA (Baku, Azerbaijan)
08:30P1678Safety and effectiveness of sacubitril/valsartan in real-life practiceJenna BERGER (Cote Saint Luc, Canada)
08:30P1679Efficacy and safety of angiotensin II receptor-1 blockers administration in patient with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary diseaseAnna EVDOKIMOVA (Moscow, Russian Federation)
08:30P1680Ivabradine and heart failure: experience from a real practiceLilyana MIRCHEVA (Varna, Bulgaria)
08:30P1681Mapping heart failure: patient-level costs of an integrated care pathway 
08:30P1682Are our heart failure patients with preserved ejection fraction ready to be included in trials? Bernardo NEVES (Lisboa, Portugal)
08:30P1683CHIC trial: Can a single outpatient visit, 8 to 15 days after the hospitalization for acute heart failure, decrease the number of re-hospitalizations?Aboubakar GUEYE (Paris, France)
08:30P1684General practitioner perceptions of services for patients with advanced heart failure: a qualitative studyKathryn ORR (Belfast, United Kingdom)
08:30P1685Personalized approach to heart failure with preserved ejection fraction (HFpEF), the Maastricht experienceArantxa BARANDIARAN (Maastricht, Netherlands)
08:30P1686Hospital discharge letter quality - An important standard between hospital and community heart failure teamsAysha GOMAA (Eastbourne, United Kingdom)
08:30P1687Heart failure specialist versus general cardiologist in the management of chronic heart failure in RussiaMaria SITNIKOVA (St-Petersburg, Russian Federation)
08:30P1688Left ventricular assistance device for destination therapy: results in the west region of FrancePierre TERUIN (Nantes, France)
08:30P1689NT pro BNP - a decision factor in preventing heart failure at diabetic patientsIrina DIMITRIU (Bucharest, Romania)
08:30P1690Use of sacubitril/valsartan in a dedicated heart failure centre - real world experience from the first 110 patientsMatthew BARRETT (Dublin, Ireland)
08:30P1691Advanced age attenuates the aggravating role of salt on acute coronary syndrome patients with heart failure; results from hellenic heart failure study.Christina CHRYSOHOOU (Athens, Greece)
08:30P1692Oral use of high doses of Furosemide as an alternative to intravenous or subcutaneous way in patients with severe Congestive Heart FailureMagdalena FERNANDEZ MARTINEZ DE MANDOJANA (Mendaro, Spain)
08:30P1693Why are heart failure patients in a district general hospital not being discharged on mineralocorticoid receptor antagonists?Elen Hanna HUGHES (Rhyl, United Kingdom)
08:30P1694Pending heart failure clinic opening: care performance measures in real-life practice Svetlana VILLEVALDE (Moscow, Russian Federation)
08:30P1695The difference between drug usage in patients with HFrEF and HFmrEF: results from TREAT HFAhmet CELIK (Mersin, Turkey)
08:30P1696The effects of prolonged daytime fasting on clinical and laboratory parameters of heart failure patients treated with diureticsMedhat SOLIMAN (Abudhabi, United Arab Emirates)
08:30P1697Impact of Ivabradine to improve the heart rate variability in patients with chronic heart failureKrasimira HRISTOVA (Sofia, Bulgaria)
08:30P1698Effects of sacubitril/valsartan vs. enalapril in paediatric patients with heart failure due to systemic LV systolic dysfunction: Design and rationale of the PANORAMA-HF studyFabian CHEN (Rahway, United States of America)
08:30P1699Safety of sacubitril/valsartan in patients receiving statins in the PARADIGM-HF trialBogdan BALAS (Basel, Switzerland)
08:30P1700Achievement of optimal medication doses during the heart failure titration processSadhbh O'LEARY (Dublin, Ireland)
08:30P1701Frusemide adjustment in heart failure HF) during ramadhan: effectiveness and safety pilot study.Kwok Kang CHOW (Kota Kinabalu, Malaysia)
08:30P1702Rationale and design of TRANSITION: a multi-center, randomised, open-label study comparing pre- versus post-discharge initiation of sacubitril/valsartan in hospitalised patients with ADHF and HFrEFDomingo Andres PASCUAL FIGAL (Murcia, Spain)
08:30P1703A double-blind, randomised, two arm parallel group trial to determine the effects of torasemide versus furosemide on one marker (PIP) of cardiac fibrosis in patient with HFpEF and T2DMTobias Daniel TRIPPEL (Berlin, Germany)
08:30P1704Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved ejection fractionLiana TUMASYAN (Yerevan, Armenia)
08:30P1705Results of a single center experience on 200 consecutive patients treated with Entresto (sacubitril/valsartan).Anne-Sophie CANU (Bordeaux, France)
08:30P1706Collaboration cardiologists-pharmacists for improving heart failure medication management. 
08:30P1707Loop diuretic down-titration in stable chronic heart failure: role for spot urinary chloride analysis?Frederik Hendrik VERBRUGGE (Heusden-Zolder, Belgium)
08:30P1708One-year outcome in patients with heart failure with mid-range ejection fraction hospitalized due to worsening heart failureMichal MARCHEL (Warsaw, Poland)
08:30P1709Heart failure with recovered ejection fraction: clinical characteristics, determinants and prognosis.Rosa Maria AGRA BERMEJO (Teo, Spain)
08:30P1710Features of congestive heart failure in patients with post-MI one year after 
08:30P1711Prognostic value of different cardiohepatic syndrome variants during the chronic heart failureYuliya SHAPOSHNIKOVA (Kharkiv, Ukraine)
08:30P1712Validation of the seattle heart failure model (SHFM) in an Iranian heart failure populationMohammadhossien SOLTANE (Yazd, Iran (Islamic Republic of))
08:30P1713Frailty conferred incremental prognostic significance in Chinese heart failure patients with advanced heart failure Katherine FAN (Aberdeen, Hong Kong SAR People's Republic of China)
08:30P1714Is serum uric acid level an independent predictor for prognosis in advanced systolic heart failure patients with diabetes mellitus?Dilek URAL (Istanbul, Turkey)
08:30P1715The history of syncope as a risk factor for hospitalization and mortality - A robust predictor for all heart failure patients?Djawid HASHEMI (Berlin, Germany)
08:30P1716Endothelial progenitor cells and apoptotic endothelial cell-derived microparticle as biomarker of chronic heart failure phenotypeAlexander E BEREZIN (Zaporizhzhya, Ukraine)
08:30P1717N-terminal fragment of proBNP holds prognostic value in very elderly patients with systolic heart failureAlessandro VALLEGGI (Pisa, Italy)
08:30P1718Low serum chloride levels in patients with heart failure: clinical associations and prognostic significancePierpaolo PELLICORI (Hull, United Kingdom)
08:30P1719Upgrade of the Barcelona-Bio-HF-calculator: incorporating risk of HF hospitalization and extending risk prediction up to 5 yearsJose LUPON (Badalona, Spain)
08:30P1720Clinical characteristics and outcomes of patients with heart failure with mid-range ejection fraction.Nuria FARRE (Barcelona, Spain)
08:30P1721The prognostic impact of subclinical hypothyroidism in heart failureMaria Luisa MALVAR (Vila Nova De Famalicao, Portugal)
08:30P1722Aldosterone receptor antagonists decrease mortality and CV hospitalizations in CHF with reduced left ventricular ejection fraction(LVEF), but not in CHF with preserved LVEF. A metaanalysis of RCTsRenato DE VECCHIS (Naples, Italy)
08:30P1723The importance of heart rate as a predictor of cardiac functional recovery in newly diagnosed heart failureAli VALIKA (Naperville, United States of America)
08:30P1724Prognostic implication of right and left-sided hemodynamic congestion in patients with heart failurePiotr ROZENTRYT (Zabrze, Poland)
08:30P1725Prognostic value of presence, amount and location of myocardial fibrosis detected by contrast enhanced cardiac magnetic resonance in patients with idiopathic dilated cardiomyopathy Laura LUPI (Brescia, Italy)
08:30P1726Characteristics of heart failure patients in indonesiaBirry KARIM (Jakarta, Indonesia)
08:30P1728Review of 115 cases of chronic heart failure with reduced ejection fraction in Tunisian Public hospitalHabiba DRISSA (Tunis, Tunisia)
08:30P1730The effect of 6-month therapy with sildenafil on the intracardiac hemodynamic and inflammation markers in pts with right ventricular dilated cardiomyopathy 
08:30P1731Insulin resistance evaluation in patients with coronary artery disease and chronic heart failure without evident disorders of carbohydrate metabolismKurmanbekova BERMET (Bishkek, Kyrgyzstan)
08:30P1732The role of anti-oxidants in the treatment of congestive heart failureTheodoros MICHAILIDIS (Alexandria, Greece)
08:30P1733Heart failure hospitalization: a decade-long trend overview in a Tertiary Care CenterGiuseppe DI STOLFO (San Giovanni Rotondo, Italy)
08:30P1734Predictors of non-response to physical rehabilitation in patients with chronic heart failureVictoria GALENKO (Saint Petersburg, Russian Federation)
08:30P1735sST2 and copeptin activity closely associated with E/E' changes during NT-proBNP guided therapy in high risk patients with chronic heart failure after acute decompensation 
08:30P1737Galectin-3, longitudinal strain and left ventricular remodelling in patients with aortic stenosisLucia Nelica AGOSTON VAS COLDEA (Cluj-Napoca, Romania)
08:30P1738Trends of heart failure hospitalization during a large period of eleven years.Maria Lucia FERNANDEZ GASSO (Jaen, Spain)
08:30P17396 minute walk distance, NYHA class and hemoglobin levels best predict health related quality of life in chronic stable heart failure patients 
08:30P1740Xanthine metabolism in patients with chronic heart failure and concomitant chronic kidney disease.Alexandr BILCHENKO (Kharkov, Ukraine)
08:30P1741Prevalence geriatric syndromes among outpatients with and without chronic heart failureYulia KOTOVSKAYA (Moscow, Russian Federation)
08:30P1742Wall motion score index evaluating myocardial performance to assess left ventricular function appropriate to be use at the bedsideMara GOMES (Rio De Janeiro, Brazil)
08:30P1743Heart failure with mid-range ejection fraction - an echocardiographic finding or a clinical phenotype?Anca Daniela FARCAS (Cluj Napoca, Romania)
08:30P1744The frequency of heart failure after acute coronary syndrome in patients with nonobstructive coronary atherosclerosisSaiana GOMBOEVA (Tomsk, Russian Federation)
08:30P1745The impact of a specialised community service on heart failure admissionsElise CHUA (London, United Kingdom)